CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: Two case reports

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4256-4258

  Abruzzese, E ^a   Cantonetti, M ^a   Morino, L ^a   Orlandi, G ^a   Tendas, A ^a   Del Principe, M I ^a   Masi, M ^a   Amadori, S ^a   Orlandi, A ^a   Anemona, L ^a   Campione, Elena ^b  

^a Department of Hematology ^*  (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; BRAIN TUMOR; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG RESISTANCE; GENETICS; HEMATOLOGIC DISEASE; HUMAN; LETTER; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SKIN NEOPLASMS;

EID: 0642347553     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.99.170     Document Type: Letter

References (15)

1. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myeloid leukaemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science 247: 824-830, 1990
2. Heisterkamp N, Stephenson JR, Groffen J, et al: Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306: 239-242, 1983
3. Deininger MWN, Goldman JM, Lydon N, et al: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 90: 3691-3698, 1997
4. Marley SB, Deininger MWN, Davidson RJ, et al: The tyrosine kinase inhibitor STI571, like interferon- preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol, 28: 551-557, 2000
5. Talpaz DM: STI-571 in chronic myelogenous leukaemia. Br J Haematol 119: 15-24, 2002
6. Hehlmann R: Trial of STI571 before proceeding to allografting for CML? Leukemia 14: 1560-1562, 2000
7. Buchdunger E, Cioffi CL, Law N, et al: The abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-kit and PDGF receptors. J Pharmacol Exp Ther 295: 139-145, 2000
8. Kilic T, Alberta JA, Zdunek M, et al: Intracranial ihibition of PDGF-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60: 5143-5150, 2000
9. Au WY, Lie AKW, Wan SK, et al: Philadelphia (Ph) chromosomepositive chronic myeloid leukaemia relapsing as Ph-negative leukaemia after allogeneic bone marrow transplantation. Br J Haematol 114: 365-368, 2001
10. Ichinohasama R, Miura I, Takahashi N, et al: Ph-negative non- Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukaemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: Report of two cases and review of the literature. Leukemia 14: 169-182, 2000
11. del Pilar Moreno M: A novel BCR-ABL fusion transcript (e15az) in 2 patients with atypical chronic myeloproliferative syndrome. Blood 97: 3668-3669, 2001
12. Petzer AL, Gunsilius E, Hayes M, et al: Low concentration of STI571 in the cerebrospinal fluid: A case report. Br J Hematol 117: 623-625, 2002
13. Takayama N, Sato N, O'Brien SG, et al: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Hematol 119: 106-108, 2002
14. Andersen MK: Clonal Ph'negative hematopoiesis in CML after therapy with imatinib mesylate is frequently chracterized by trisomy 8. Leukemia 16: 1390-1395, 2002
15. O'Dwyer ME, Gatter KM, Loriaux M, et al: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukaemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17: 481-487, 2003